The Health-RI cBioPortal provides a web-based resource for researchers to explore, visualize, analyze, and share multidimensional cancer genomics data sets as well as other studies with multidimensional genomics data.
Visualizations include survival analysis, networks analysis, co-expression and the onco-print (gene-print). Furthermore, a study view provides summary statistics of your clinical data allowing to create a subset of your data for further analysis.
The portal supports a variety of genomic data types, including somatic mutations, DNA copy-number alterations (CNAs), mRNA and microRNA (miRNA) expression, DNA methylation, protein abundance, and phosphoprotein abundance.
To protect your data, the cBioPortal hosted by Health-RI has access policies, meaning that as a study owner you can decide which users have access to your studies.
No bioinformatics expertise required.
For further questions regarding this Health-RI platform, including requests for usage, please contact the Health-RI ServiceDesk.
To use cBioPortal for your study data, contact the Health-RI ServiceDesk. Only the PI of the study (or a delegate with explicit consent of the PI) can make the request to use cBioPortal for their study. If approved, then the service desk will send further information to the PI. It is then the PI’s responsibility to provide other users within the study with do’s and don’t and to ensure that they act accordingly.
The Servicedesk will provide 1st and 2nd line user support.
‘Final’ or ‘processed’ data, derived from a data-freeze, can be uploaded by the PI but also by other users within the study such as data Extraction, Transformation and Loading (ETL) experts.
If you would like to have access to a study already in cBioPortal but do not have access to the Health-RI platform, please mail the Health-RI ServiceDesk to request the necessary access.
cBioPortal was originally developed at Memorial Sloan Kettering Cancer Center (MSK), the portal became open source in 2011 and is used by tens of thousands of researchers worldwide.
The portal is actively developed and maintained by a multi-institutional team, consisting of MSK, the Dana Farber Cancer Institute, Princess Margaret Cancer Centre in Toronto, Children's Hospital of Philadelphia, The Hyve in the Netherlands, and Bilkent University in Ankara, Turkey.
- Cerami et al: The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
- Gao et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal
Current version and release notes
cBioPortal v3.1.2 (GNU Affero General Public License v3.0, original source code)
Bart Koopman M.D., researcher PATH project and Ph.D. candidate UMCG
cBioPortal enables us to efficiently visualize, analyze and share complex mutational landscapes in cancer patients to rationalize new targeted therapy options